secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0000950170-24-020183
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux announces encouraging safety/efficacy data for JANX007 in mCRPC and JANX008 in solid tumors
--------------------------------------------------------------------------------

- JANX007: 5/6 (83%) PSA50 declines at step dose ≥0.2 mg; 10/18 (56%) at ≥0.1 mg; no Grade 3+ CRS.
- JANX008: NSCLC subject achieved confirmed PR with 100% target lung lesion reduction and elimination of liver metastasis; no CRS or TRAEs.
- JANX008: No Grade 2+ CRS, no treatment-related SAEs or DLTs across 11 heavily pretreated patients across 4 tumor types.
- Janux hosting virtual investor event today at 4:30 PM ET to discuss data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024020183/0000950170-24-020183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024020183/janx-20240226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-020183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer